Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 06, 2024 07:00 ET
|
Omega Therapeutics
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data...
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 06, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and...
Join Mobilicom’s Exclusive Live Investor Webinar and Q&A Session on May 9
May 06, 2024 07:00 ET
|
Mobilicom Limited
SHOHAM, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, is pleased to invite investors to a...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q...
The Simply Good Foods Company to Participate in the Goldman Sachs Global Staples Forum
May 06, 2024 07:00 ET
|
Simply Good Foods USA, Inc.
DENVER, May 06, 2024 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (NASDAQ:SMPL) (“Simply Good Foods” or the “Company”), a developer, marketer and seller of branded nutritional foods and...
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs,...
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
May 06, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no...
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
May 06, 2024 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Bank of America Securities Healthcare...
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...